Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
|Articles|February 1, 2005
- Volume 0 0
Reminyl Will Receive New Name
Advertisement
Johnson & Johnson is renaming itsAlzheimer's disease drug Reminyl(galantamine HBr). Although the companyand the FDA have not agreed onthe new name, the change is expectedto be introduced by the end of March2005. The decision to changeReminyl's name comes after 2 patientsdied when they were mistakenly givena similar-sounding drug—Amaryl(glimepiride). Amaryl (Sanofi-Aventis)is indicated for the treatment of diabetes.The deaths were caused by hypoglycemiaor low blood sugar when thepatients were given Amaryl.
Articles in this issue
over 21 years ago
Issues in the Treatment of Patients with Hypothyroidismover 21 years ago
Health Organizations Favor Electronic Health Recordsover 21 years ago
Therapeutic Management of Bronchitisover 21 years ago
Program Advocates for Timely Prescription Refillsover 21 years ago
Cardinal Backs RFID Technologyover 21 years ago
Agreement Improves Point of Careover 21 years ago
Decision Unpopular with Health Care Professionalsover 21 years ago
The Importance of the Order of Drug Administrationover 21 years ago
Beware of Erroneous Daily Oral Methotrexate Dosing!Advertisement
Related to this article
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Intensive Chemotherapy in Combination With Quizartinib Versus Midostaurin for FLT3-ITD Mutated Acute Myeloid Leukemia: A Multicenter Cohort Study
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
4
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
5